Search Results - "Obourn, Vanessa"

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis by Radich, Jerald P, Wall, Matthew, Branford, Susan, Campbell, Catarina D, Chaturvedi, Shalini, DeAngelo, Daniel J, Deininger, Michael, Guinney, Justin, Hochhaus, Andreas, Hughes, Timothy P, Kantarjian, Hagop M, Larson, Richard A, Li, Sai, Maegawa, Rodrigo, Mishra, Kaushal, Obourn, Vanessa, Pinilla-Ibarz, Javier, Purkayastha, Das, Sadek, Islam, Saglio, Giuseppe, Shrestha, Alok, White, Brian S, Druker, Brian J

“…Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to…”
Get full text

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial by Branford, Susan, Hochhaus, Andreas, Mauro, Michael, Minami, Yosuke, Rea, Delphine, Boquimpani De Moura Freitas, Carla Maria, Serrano-Fernandez, Pablo, Obourn, Vanessa, Bruederle, Andreas, Espurz, Noemi, Hughes, Timothy P

“…Somatic mutations in blood cancer-related genes are commonly detected in CML-AP. The most frequently mutated genes are RUNX1, ASXL1 IKZF1 (submicroscopic…”
Get full text

Clinical Pharmacology of Asciminib: A Review by Hoch, Matthias, Huth, Felix, Manley, Paul William, Loisios-Konstantinidis, Ioannis, Combes, Francois Pierre, Li, Ying Fei, Fu, Yunlin, Sy, Sherwin K. B., Obourn, Vanessa, Chakraborty, Abhijit, Hourcade-Potelleret, Florence

“…Asciminib is a first-in-class allosteric inhibitor of the kinase activity of BCR::ABL1, specifically targeting the ABL myristoyl pocket (STAMP). This review…”
Get full text

RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia by Shanmuganathan, Naranie, Wadham, Carol, Thomson, Daniel, Shahrin, Nur H., Vignaud, Chloe, Obourn, Vanessa, Chaturvedi, Shalini, Yang, Feng, Feng, Jinghua, Saunders, Verity, Kok, Chung H., Yeung, David, King, Rob M., Kenyon, Rosalie R., Lin, Ming, Wang, Paul, Scott, Hamish, Hughes, Timothy, Schreiber, Andreas W., Branford, Susan

“…Mutation detection is increasingly used for the management of hematological malignancies. Prior whole transcriptome and whole exome sequencing studies using…”
Get full text

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd by Radich, Jerald P., Larson, Richard A., Kantarjian, Hagop M., Deininger, Michael W., Pinilla Ibarz, Javier, DeAngelo, Daniel J., Branford, Susan, Sadek, Islam, Chaturvedi, Shalini, Sondhi, Manu, Wall, Matthew, Mishra, Kaushal, Purkayastha, Das, Shrestha, Alok, Obourn, Vanessa, White, Brian S., Druker, Brian J.

“…Background: Achieving sustained DMR (variably described as ≥ MR4 or ≥ MR4.5) is an emerging treatment goal for patients with CML. DMR is associated with…”
Get full text

CML-109: Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML) by Radich, Jerald, Larson, Richard, Kantarjian, Hagop, Deininger, Michael, Pinilla-Ibarz, Javier, DeAngelo, Daniel, Branford, Susan, Sadek, Islam, Chaturvedi, Shalini, Wall, Matthew, Mishra, Kaushal, Purkayastha, Das, Shrestha, Alok, Obourn, Vanessa, White, Brian, Druker, Brian

“…For patients with CML, achieving sustained DMR is a prerequisite for attempting treatment-free remission. However, biomarkers that predict DMR are unknown…”
Get full text

PolyPhred analysis software for mutation detection from fluorescence-based sequence data by Montgomery, Kate T, Iartchouck, Oleg, Li, Li, Loomis, Stephanie, Obourn, Vanessa, Kucherlapati, Raju

“…The ability to search for genetic variants that may be related to human disease is one of the most exciting consequences of the availability of the sequence of…”
Get more information